Literature DB >> 11989974

Alterations of HLA class I and class II antigen expressions in borderline, invasive and metastatic ovarian cancers.

Youn Soo Le1, Tae Eung Kim, Byung Kee Kim, Yong Gyu Park, Gyu-Moon Kim, Sung-Bae Jee, Ki Sung Ryu, In-Kyung Kim, Jin Woo Kim.   

Abstract

In an effort to understand whether HLA class I and II plays any role in the process of tumorigenesis and metastasis, we have immunohistochemically examined expression of HLA class I and II antigen by using the monoclonal antibodies (mAb) L368 (for beta2m of HLA class I), HC-10 (for HLA-B, C heavy chains), and LGII-612.14 (for HLA class II heavy chain) in 5 borderline serous malignancy (BSM), 20 serous adenocarcinomas (SA), 15 borderline mucinous malignancy (BMM), and 10 mucinous adenocarcinomas (MA) of human ovary tumor case tissues. In BSM, the distribution and intensity of HLA expressions failed to reach statistical significance. In SA, HLA class I beta2-microglobulin (beta2m), HLA-B, C heavy chains and HLA class II heavy chain antigen expressions were down-regulated. Although expressions of HLA-B, C heavy chains and class II heavy chain were down-regulated in metastatic SA, there were no differences in HLA expression levels between primary and metastatic lesions. In BMM, class II heavy chain expressions were down-regulated. In MA, beta2m, HLA-B, C heavy chains and class II heavy chain expressions were also down-regulated. Thus, we could distinguish the reduction or absence of HLA molecule expression was related to malignant potential. Loss of HLA class I and II molecules in invasive ovarian cancers raises the possibility that this could be a factor for tumor cells to retain invasiveness.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11989974     DOI: 10.1038/emm.2002.3

Source DB:  PubMed          Journal:  Exp Mol Med        ISSN: 1226-3613            Impact factor:   8.718


  6 in total

1.  Expression of HLA-I, CD8, and CD4 and Their Clinical Significance in Cervical Cancer.

Authors:  Jiang Tao Fan; Yan Liao; Xiao Hui Si; Xiao Li Geng; Wei Wei; Qing Li Xie
Journal:  World J Oncol       Date:  2011-02-26

2.  Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer.

Authors:  Emilia Andersson; Lisa Villabona; Kjell Bergfeldt; Joseph W Carlson; Soldano Ferrone; Rolf Kiessling; Barbara Seliger; Giuseppe V Masucci
Journal:  Cancer Immunol Immunother       Date:  2012-01-19       Impact factor: 6.968

3.  Checkpoint Blockade: Not Yet NINJA Status in Ovarian Cancer.

Authors:  Rebecca L Porter; Ursula A Matulonis
Journal:  J Clin Oncol       Date:  2021-09-16       Impact factor: 44.544

4.  La protein regulates protein expression by binding with the mRNAs of target genes and participates the pathological process of ovarian cancer.

Authors:  Xuan Huang; Jialei Zhu; Yueyan Li; Yang Yu; Jing Tang
Journal:  Front Oncol       Date:  2022-08-30       Impact factor: 5.738

5.  Direct tumor recognition by a human CD4(+) T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses.

Authors:  Junko Matsuzaki; Takemasa Tsuji; Immanuel F Luescher; Hiroshi Shiku; Junichi Mineno; Sachiko Okamoto; Lloyd J Old; Protul Shrikant; Sacha Gnjatic; Kunle Odunsi
Journal:  Sci Rep       Date:  2015-10-08       Impact factor: 4.379

6.  Reference Module-Based Analysis of Ovarian Cancer Transcriptome Identifies Important Modules and Potential Drugs.

Authors:  Xuedan Lai; Peihong Lin; Jianwen Ye; Wei Liu; Shiqiang Lin; Zhou Lin
Journal:  Biochem Genet       Date:  2021-06-25       Impact factor: 1.890

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.